Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody iSCIB1+
July 22, 2025 02:00 ET | Source: Scancell Holdings Plc SCOPE trial…
UnionPay Launches Global Summer Campaign with Exclusive Travel Offers
Exclusive discounts, cashback, and exchange rate perks for international travelers SHANGHAI, July…
OMD TOPS GLOBAL MEDIA AGENCY RANKING
Omnicom Media Group Agency Outperforms the Industry for Billings Volume and Net Growth…
India’s Urban Population to Reach 600 Million by 2036: Primus Partners Report
Urbanization on the Rise: India's urbanization rate, which stood at 31% in…
Tirupati, India, Among Asia’s Most Affordable Summer Destinations in 2025: Agoda
Digital travel platform Agoda has revealed its list of the most budget-friendly…
CoinDesk Overnight Rates (CDOR) to Support Stablecoin Money Markets based on Aave
These first-of-kind money market rates transform Aave pool activity into conventional overnight…
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial…
Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9…
Dentsply Sirona Prices Offering of $550 million of Junior Subordinated Notes
June 05, 2025 17:35 ET | Source: DENTSPLY SIRONA Inc. CHARLOTTE, N.C.,…